Vaccination strategies for the prevention of meningococcal disease

References

• Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis. 1999;180(6):1894–901. doi:10.1086/315158. PMID:10558946.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease. [accessed 2017 October 2] http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/mening.pdf.
   Google Scholar
• Kimberlin DW, Brady MT, Jackson MA, Long SS, (Eds.). Red Book 2015. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015. p. 152.
   Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta–analysis. Lancet Infect Dis. 2010;10(12):853–61 doi:10.1016/S1473-3099(10)70251-6. PMID:21075057.
   PubMed Web of Science ®Google Scholar
• Caugant DA, Hoiby EA, Magnus P, Scheel O, Hoel T, Bjune G, Wedege E, Eng J, Froholm LO. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol. 1994;32(2):323–30. PMID:8150942.
   PubMed Web of Science ®Google Scholar
• Carbonnelle E, Hill DJ, Morand P, Griffiths NJ, Bourdoulous S, Murillo I, Nassif X, Virji M. Meningococcal interactions with the host. Vaccine. 2009;27(suppl 2):B78–89. doi:10.1016/j.vaccine.2009.04.069. PMID:19481311.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31(1):101–7. doi:10.1111/j.1574-6976.2006.00053.x. PMID:17168998.
   PubMed Web of Science ®Google Scholar
• Environmental Health Indicators New Zealand. Notifications of meningococcal disease. [accessed 2017 October 2] http://www.ehinz.ac.nz/assets/Factsheets/Released-2015/EHI72-NotificationsOfMeningococcalDiseaseInNZ1997-2014-released201508.pdf.
   Google Scholar
• Mohammed I, Nasidi A, Alkali AS, Garbati MA, Ajayi-Obe EK, Audu KA, Usman A, Abdullahi S. A severe epidemic of meningococcal meningitis in Nigeria, 1996. Trans R Soc Trop Med Hyg. 2000;94(3):265–70. doi:10.1016/S0035-9203(00)90316-X. PMID:10974995.
   PubMed Web of Science ®Google Scholar
• Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century-an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(3):2. doi:10.1007/s11910-015-0524-6. PMID:25637287.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal Meningitis Fact Sheet No 141. [accessed 2017 October 16] http://www.who.int/mediacentre/factsheets/fs141/en/#.
   Google Scholar
• Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566–73 doi:10.3201/eid1904.111799. PMID:23628376.
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–210 doi:10.1016/S0140-6736(07)61016-2. PMID:17604802.
   PubMed Web of Science ®Google Scholar
• Mueller JE, Gessner BD. A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt. Int J Infect Dis. 2010;14(7):e553–559. doi:10.1016/j.ijid.2009.08.013. PMID:20018546.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Reducing mortality from emerging diseases. Wkly Epidemiol Rec. 2015;90:121–3. PMID:25816447.
   PubMedGoogle Scholar
• Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Mainassara HB, Tenebray B, Kairo KK, Giorgini D, Chanteau S. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44(5):657–63 doi:10.1086/511646. PMID:17278055.
   PubMed Web of Science ®Google Scholar
• Gagneux SP, Hodgson A, Smith TA, Wirth T, Ehrhard I, Morelli G, Genton B, Binka FN, Achtman M, Pluschke G. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis. 2002;185(5):618–26. doi:10.1086/339010. PMID:11865418.
   PubMed Web of Science ®Google Scholar
• Materu S, Cox HS, Isaakidis P, Baruani B, Ogaro T, Caugant DA. Serogroup X in meningococcal disease, Western Kenya. Emerg Infect Dis. 2007;13(6):944–5. doi:10.3201/eid1306.070042. PMID:17582900.
   PubMed Web of Science ®Google Scholar
• Delrieu I, Yaro S, Tamekloe TA, Njanpop-Lafourcade BM, Tall H, Jaillard P, Ouedraogo MS, Badziklou K, Sanou O, Drabo A, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS ONE. 2011;6(5):e19513. doi:10.1371/journal.pone.0019513. PMID:21625480.
   PubMed Web of Science ®Google Scholar
• World Health Organization.Rapidly growing outbreak of meningococcal disease in Niger. 2015. [accessed 2018 March 20] http://www.who.int/mediacentre/news/situation-assessments/meningitis-niger/en/.
   Google Scholar
• Hossain MJ, Roca A, Mackenzie GA, Jasseh M, Hossain MI, Muhammad S, Ahmed M, Chidiebere OD, Malick N, Bilquees SM, et al. Serogroup W135 meningococcal disease, The Gambia, 2012. Emerg Infect Dis. 2013;19(9):1507–10. doi:10.3201/eid1909.130077. PMID:23965435.
   PubMed Web of Science ®Google Scholar
• Carville KS, Stevens K, Sohail A, Franklin LJ, Bond KA, Brahmi A, Romanes F, Ong KS. Increase in meningococcal serogroup W disease, Victoria, Australia, 2013–2015. Emerg Infect Dis. 2016;22(10):1785–7 doi:10.3201/eid2210.151935. PMID:27648521.
   PubMed Web of Science ®Google Scholar
• Yousuf M, Nadeem A. Fatal meningococcaemia due to group W135 amongst Haj pilgrims: implications for future vaccination policy. Ann Trop Med Parasitol. 1995;89(3):321–2 doi:10.1080/00034983.1995.11812960. PMID:7668926.
   PubMed Web of Science ®Google Scholar
• Lingappa JR, Al-Rabeah AM, Hajjeh R, Mustafa T, Fatani A, Al-Bassam T, Badukhan A, Turkistani A, Makki S, Al-Hamdan N, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis. 2003;9(6):665–71. doi:10.3201/eid0906.020565. PMID:12781005.
   PubMed Web of Science ®Google Scholar
• Aguilera JF, Perrocheau A, Meffre C, Hahne S, W135 working group outbreak of serogroup W135 meningococcal disease after the hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8(8):761–7. doi:10.3201/eid0808.010422.
   Google Scholar
• Abad R, Lopez EL, Debbag R, Vazquez JA. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142(12):2461–70 doi:10.1017/S0950268814001149. PMID:24831052.
   PubMed Web of Science ®Google Scholar
• Tsang RSW, Deeks SL, Wong K, Marchand-Austin A, Jamieson FB. Invasive serogroup W Neisseria meningitidis (MenW) in Ontario, Canada shows potential clonal replacement during the period January 1, 2009 to June 30, 2016. [accessed 2017 March 27] http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/16vol42/dr-rm42-12/ar-06-eng.php.
   Google Scholar
• Public Health England. Meningococcal disease: laboratory confirmed cases in England and Wales; invasive meningococcal C infections by epidemiological year and age group, England. (1998 and 1999 to 2014 and 2015). [accessed 2017 November 2] https://www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmed-cases-in-england-and-wales.
   Google Scholar
• Lucidarme J, Hill DM, Bratcher HB, Gray SJ, du Plessis M, Tsang RS, Vazquez JA, Taha MK, Ceyhan M, Efron AM, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect. 2015;71(5):544–52 doi:10.1016/j.jinf.2015.07.007. PMID:26226598.
   PubMed Web of Science ®Google Scholar
• Campbell H, Parikh SR, Borrow R, Kaczmarski E, Ramsay ME, Ladhani SN. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro Surveill. 2016;21(12) doi:10.2807/1560-7917.ES.2016.21.12.30175. PMID: 27035055.
   PubMedGoogle Scholar
• Rodriguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz. 1999;94(4):433–40 doi:10.1590/S0074-02761999000400002. PMID:10445998.
   PubMed Web of Science ®Google Scholar
• Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, Froholm LO, Lindbak AK, Mogster B, Namork E, Rye U, et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 1991;14(2):67–79; discussion 79–80. PMID:1812438.
   PubMedGoogle Scholar
• Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis. 1998;177(2):497–500. doi:10.1086/517385. PMID:9466547.
   PubMed Web of Science ®Google Scholar
• Dyet KH, Martin DR. Clonal analysis of the serogroup B meningococci causing New Zealand's epidemic. Epidemiol Infect. 2006;134(2):377–83. doi:10.1017/S0950268805004954. PMID:16490143.
   PubMed Web of Science ®Google Scholar
• Grodet C, Dequin PF, Watt S, Lanotte P, de Gialluly C, Taha MK, Alonso JM, Quentin R, Goudeau A, Mereghetti L. Outbreak in france of neisseria meningitidis B:15:P1.12 belonging to sequence type 1403. Clin Microbiol Infect. 2004;10(9):845–8. doi:10.1111/j.1469-0691.2004.00935.x. PMID:15355418.
   PubMed Web of Science ®Google Scholar
• Caron F, du Chatelet IP, Leroy JP, Ruckly C, Blanchard M, Bohic N, Massy N, Morer I, Floret D, Delbos V, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11(6):455–63 doi:10.1016/S1473-3099(11)70027-5. PMID:21489881.
   PubMed Web of Science ®Google Scholar
• Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608–12. PMID:26068564.
   PubMed Web of Science ®Google Scholar
• Atkinson B, Gandhi A, Balmer P. History of meningococcal outbreaks in the United States: implications for vaccination and disease prevention. Pharmacotherapy. 2016;36(8):880–92. doi:10.1002/phar.1790. PMID:27332671.
   PubMed Web of Science ®Google Scholar
• Mandal S, Wu HM, MacNeil JR, Machesky K, Garcia J, Plikaytis BD, Quinn K, King L, Schmink SE, Wang X, et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis. 2013;57(3):344–8. doi:10.1093/cid/cit243. PMID:23595832.
   PubMed Web of Science ®Google Scholar
• Biswas HH, Han GS, Wendorf K, Winter K, Zipprich J, Perti T, Martinez L, Arellano A, Kyle JL, Zhang P, et al. Notes from the field: outbreak of serogroup B meningococcal disease at a University – California, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(20):520–1 doi:10.15585/mmwr.mm6520a3. PMID:27227576.
   PubMed Web of Science ®Google Scholar
• Rutgers Student Health. Rutgers recommends meningitis B vaccine. [accessed 2016 August 31] http://health.rutgers.edu/meningitis/.
   Google Scholar
• Oregon State University Student Health Services. Meningococcal Disease. [accessed 2018 February 12] http://studenthealth.oregonstate.edu/meningococcal-disease.
   Google Scholar
• OSU hit with 6th case of meningococcal disease; all students under 26 will need a vaccination. [accessed 2018 February 12] http://www.oregonlive.com/health/index.ssf/2017/12/osu_hit_with_6th_case_of_menin.html.
   Google Scholar
• Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50(suppl 2):S37–44 doi:10.1086/648963. PMID:20144015.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364(9431):365–7. doi:10.1016/S0140-6736(04)16725-1. PMID:15276396.
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA. 2004;292(20):2491–4. doi:10.1001/jama.292.20.2491. PMID:15562128.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA. Investigators of the canadian immunization monitoring program , ACTive. The impact of the meningococcal serogroup c conjugate vaccine in canada between 2002 and 2012. Clin Infect Dis. 2014;59(9):1208–15 doi:10.1093/cid/ciu597. PMID:25069868.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, Ramsay ME, Kaczmarski EB, Borrow R. Invasive meningococcal capsular group Y disease, England and Wales, 2007–2009. Emerg Infect Dis. 2012;18(1):63–70. doi:10.3201/eid1801.110901. PMID:22261040.
   PubMed Web of Science ®Google Scholar
• Toros B, Hedberg ST, Unemo M, Jacobsson S, Hill DM, Olcen P, Fredlund H, Bratcher HB, Jolley KA, Maiden MC, et al. Genome-based characterization of emergent invasive Neisseria meningitidis serogroup Y isolates in Sweden from 1995 to 2012. J Clin Microbiol. 2015;53(7):2154–62. doi:10.1128/JCM.03524-14. PMID:25926489.
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(suppl 1):S58–67. doi:10.1016/S0264-410X(01)00299-7. PMID:11587814.
   PubMed Web of Science ®Google Scholar
• Meningtec® (Meningococcal serogroup C oligosaccharide conjugate vaccine). Package Leaflet: Information for the User, Pfizer Ltd, Kent, UK, 2011.
   Google Scholar
• Menjugate® (Meningococcal Group C–CRM197 Conjugate Vaccine). Product Monograph, GlaxoSmithKline Inc, Ontario, Canada, 2015.
   Google Scholar
• NeisVac-C® (Meningococcal group C polysaccharide conjugate vaccine adsorbed). Product Monograph, Pfizer Ltd, Kent, UK, 2016.
   Google Scholar
• Handysides S. Vaccination programme for group C meningococcal infection is launched in the United Kingdom. Eurosurveillance. 1999;3(30):1365.
   Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365–6. doi:10.1136/bmj.326.7385.365. PMID:12586669.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Stuart JM. U. K. Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829–31. doi:10.1016/S0140-6736(02)08679-8. PMID:12044380.
   PubMed Web of Science ®Google Scholar
• Health England. Meningococcal: the Green Book, Chapter 22. [accessed 2016 August 25] https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22.
   Google Scholar
• Public Health England. Changes to the meningococcal C conjugate (MenC) vaccine schedule 2013–2015. [accessed 2017 March 27] https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/336171/MenC_information_for_healthcare_professionals_V7_.pdf.
   Google Scholar
• Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8(7):851–61. doi:10.1586/erv.09.48. PMID:19538112.
   PubMed Web of Science ®Google Scholar
• de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J. 2006;25(1):79–80. doi:10.1097/01.inf.0000195594.41449.c6. PMID:16395110.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Rubin L, McNamara L, Briere EC, Clark TA, Cohn AC, Meningitis, Vaccine Preventable Diseases Branch DoBDNCfI, Respiratory Diseases CDC. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(24):527–530. PMID:24941332.
   PubMed Web of Science ®Google Scholar
• Menactra (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine). Full Prescribing Information, Sanofi Pasteur, Swiftwater, PA. 2016.
   Google Scholar
• Menveo® (Summary of Product Characteristics, meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine). summary of product characteristics. Via Fiorentia, Italy: GSK Vaccines, Srl. 2017.
   Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup b meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–6 doi:10.15585/mmwr.mm6441a3. PMID:26492381.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1–28 PMID:23515099
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1–21.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep. 2007;56(31):794–5. PMID:17694617.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines — Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2011;60(3):72–76. PMID:21270745.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Surveillance Reports. [accessed 2017 November 29] http://www.cdc.gov/abcs/reports-findings/surv-reports.html.
   Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2) doi:10.1542/peds.2016-2193. PMID:28100689.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. JCVI position statement on use of Bexsero® meningococcal B vaccine in the UK. March 2014. [accessed 2017 October 2] https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/294245/JCVI_Statement_on_MenB.pdf.
   Google Scholar
• Bexsero (meningococcal group B vaccine). Full Prescribing Information, Novartis, Cambridge, MA: 2016.
   Google Scholar
• Bexsero® (meningococcal group B vaccine). Summary of Product Characteristics. GlaxoSmithKline Research Triangle Park, NC. 2017.
   Google Scholar
• Public Health England. Immunisation against meningococcal B disease for infants aged from two months. [accessed 2018 February 12] https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/501588/PHE_MenB_informationforhealthprofessionals_FINAL_18022016.pdf.
   Google Scholar
• National Health Service. Using paracetamol to prevent and treat fever after MenB vaccination. [accessed January 4 2018] https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/483408/9413-paracetamol-menB-2page-A4-08-web.pdf.
   Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–82. doi:10.1016/S0140-6736(16)31921-3. PMID:28100432.
   PubMed Web of Science ®Google Scholar
• Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). Hum Vaccin Immunother. 2012;8(6):715–24 doi:10.4161/hv.19619. PMID:22495119.
   PubMed Web of Science ®Google Scholar
• Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Preziosi MP, Zuber PL, Perea W, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine. 2012;30(suppl 2):B40–45. doi:10.1016/j.vaccine.2011.12.073. PMID:22607898.
   PubMed Web of Science ®Google Scholar
• Al-Mazrou Y, Khalil M, Borrow R, Balmer P, Bramwell J, Lal G, Andrews N, Al-Jeffri M. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect Immun. 2005;73(5):2932–9. doi:10.1128/IAI.73.5.2932-2939.2005. PMID:15845499.
   PubMed Web of Science ®Google Scholar
• Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24(22):4692–700 doi:10.1016/j.vaccine.2006.03.034. PMID:16621189.
   PubMed Web of Science ®Google Scholar
• Jodar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet. 2003;361(9372):1902–4. doi:10.1016/S0140-6736(03)13494-0. PMID:12788589.
   PubMed Web of Science ®Google Scholar
• LaForce FM, Okwo-Bele J-M. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood). 2011;30(7):1049–57. doi:10.1377/hlthaff.2011.0328. PMID:21653956.
   PubMedGoogle Scholar
• World Health Organization. Meningococcal A conjugate vaccine: updated guidance, February 2015. Wkly Epidemiol Rec. 2015;90(8):57–68. PMID:25702330.
   PubMedGoogle Scholar
• Novak RT, Kambou JL, Diomande FV, Tarbangdo TF, Ouedraogo-Traore R, Sangare L, Lingani C, Martin SW, Hatcher C, Mayer LW, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis. 2012;12(10):757–64 doi:10.1016/S1473-3099(12)70168-8. PMID:22818241.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine – Burkina Faso and Mali. MMWR Morb Mortal Wkly Rep. 2012;61(50):1025–8. PMID:23254257.
   PubMedGoogle Scholar
• World Health Organization. Meningitis weekly bulletin, inter country support team – West Africa. [accessed 2016 August 31] http://www.meningvax.org/epidemic-updates.php.
   Google Scholar
• Kristiansen PA, Diomande F, Wei SC, Ouedraogo R, Sangare L, Sanou I, Kandolo D, Kabore P, Clark TA, Ouedraogo AS, et al. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol. 2011;18(3):435–43. doi:10.1128/CVI.00479-10. PMID:21228139.
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouedraogo AS, Ouedraogo R, Sangare L, Kandolo D, Ake F, Saga IM, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56(3):354–63 doi:10.1093/cid/cis892. PMID:23087396.
   PubMed Web of Science ®Google Scholar
• Gamougam K, Daugla DM, Toralta J, Ngadoua C, Fermon F, Page AL, Djingarey MH, Caugant DA, Manigart O, Trotter CL, et al. Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013. Emerg Infect Dis. 2015;21(1):115–8 doi:10.3201/eid2101.140256. PMID:25536336.
   PubMed Web of Science ®Google Scholar
• Meningitis Vaccine Project. MVP News Digest, Q4 2014. [accessed 2017 March 27] http://www.meningvax.org/files/MVP_newsdigest_2014_Q4_42_EN.pdf.
   Google Scholar
• Yezli S, Wilder-Smith A, Bin Saeed AA. Carriage of Neisseria meningitidis in the Hajj and Umrah mass gatherings. Int J Infect Dis. 2016; [Accepted for publication].
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2016. Yellow Book Travelers' Health. 2016; Chapter 4 Select Destinations
   Google Scholar
• Saudi Arabia Ministry of Health. Meningococcal Meningitis. [accessed 2018 February 12] https://www.moh.gov.sa/en/Hajj/HealthGuidelines/HealthGuidelinesDuringHajj/Pages/MeningococcalMeningitis.aspx.
   Google Scholar
• Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991–2000. J Paediatr Child Health. 2001;37(5):S13–19. doi:10.1046/j.1440-1754.2001.00722.x. PMID:11885731.
   PubMedGoogle Scholar
• Holst J, Oster P, Arnold R, Tatley MV, Naess LM, Aaberge IS, Galloway Y, McNicholas A, O'Hallahan J, Rosenqvist E, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9(6):1241–53 doi:10.4161/hv.24129. PMID:23857274.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition. [accessed 2017 November 2] http://www.who.int/csr/resources/publications/meningitis/whoemcbac983.pdf.
   Google Scholar
• Dyet K, Devoy A, McDowell R, Martin D. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine. 2005;23(17-18):2228–30. doi:10.1016/j.vaccine.2005.01.050. PMID:15755601.
   PubMed Web of Science ®Google Scholar
• Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis. 2009;49(4):597–605 doi:10.1086/603552. PMID:19622040.
   PubMed Web of Science ®Google Scholar
• New Zealand Ministry of Health. Meningococcal B immunisation programme and MeNZB™ vaccine. [accessed 2017 March 27] http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/immunisation-programme-decisions/meningococcal-b-immunisation-programme-and-menzbtm-vaccine.
   Google Scholar
• Feiring B, Fuglesang JB, Oster P, Naess LM, Helland OS, Tilman S, Rosenqvist E, Bergsaker MA, Nokleby H, Aaberge IS. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol. 2006;13(7):790–6 doi:10.1128/CVI.00047-06. PMID:16829617.
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Fuglesang JE, Hoiby EA, Nokleby H, Aaberge IS, Rosenqvist E. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21(7-8):734–7. doi:10.1016/S0264-410X(02)00591-1. PMID:12531351.
   PubMed Web of Science ®Google Scholar
• Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine. 2007;25(16):3075–9 doi:10.1016/j.vaccine.2007.01.023. PMID:17289223.
   PubMed Web of Science ®Google Scholar
• Wong SH, Lennon DR, Jackson CM, Stewart JM, Reid S, Ypma E, O'Hallahan JM, Oster P, Mulholland K, Martin DR. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J. 2009;28(5):385–90 doi:10.1097/INF.0b013e318195205e. PMID:19384263.
   PubMed Web of Science ®Google Scholar
• Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol. 2007;166(7):817–23 doi:10.1093/aje/kwm147. PMID:17615088.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Bexsero EPAR summary for the public. [accessed 2017 March 27] http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002333/WC500137857.pdf.
   Google Scholar
• National Foundation for Infectious Diseases. Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses: A report by the National Foundation for Infectious Diseases. [accessed 2018 February 12] http://www.nfid.org/meningococcal-b.
   Google Scholar
• National Meningitis Association. Serogrlloup B meningococcal disease outbreaks on U.S. college campuses. [accessed 2018 February 12] http://www.nmaus.org/disease-prevention-information/serogroup-b-meningococcal-disease/outbreaks/.
   Google Scholar
• Soeters HM, McNamara LA, Whaley M, Wang X, Alexander-Scott N, Kanadanian KV, Kelleher CM, MacNeil J, Martin SW, Raines N, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college – Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606–7. PMID:26068563.
   PubMed Web of Science ®Google Scholar
• University of Oregon. Meningococcemia diagnosed in another UO student; vaccination efforts continue. [accessed 2018 February 12] http://around.uoregon.edu/content/meningococcemia-diagnosed-another-uo-student-vaccination-efforts-continue.
   Google Scholar
• Soeters H, McNamara L, Whaley M, Wang X, Alexander-Scott N, Goodwin K, Kanadanian K, Kelleher C, MacNeil J, Martin S, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college-Rhode Island. Paper presented at: IDWeek (abstract number 1872). 2015 October 7–11; San Diego, CA.
   Google Scholar
• Santa Clara County Public Health. Meningococcal Meningitis. [accessed 2016 August 31] https://www.sccgov.org/sites/sccphd/en-us/Residents/DiseaseInformation/meningitis/Pages/meningitis.aspx.
   Google Scholar
• The Associated Press. Second Oregon State student sick with meningoccocal disease. [accessed 2018 February 13] http://www.oregonlive.com/education/index.ssf/2016/11/second_oregon_state_student_si.html.
   Google Scholar
• de Serres G. Results of a mass immunization campaign with 4CmenB vaccine in the Saguenay-Lac-Saint-Jean region. Paper invited to be presented at: Meeting of the Advisory Committee on Immunization Practices (ACIP). 2016 February 24; Atlanta, GA, USA Requests for slide presentation files at [email protected].
   Google Scholar
• Banzhoff A. Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States. Ther Adv Vaccines. 2017;5(1):3–14. doi:10.1177/2051013616681365. PMID:28344804.
   PubMedGoogle Scholar
• Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123–31. doi:10.1016/S0140-6736(14)60842-4. PMID:25145775.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Frosch M. Can we, should we, eradicate the meningococcus? Vaccine. 2012;30(suppl 2):B52–56. doi:10.1016/j.vaccine.2011.12.068. PMID:22607899.
   PubMed Web of Science ®Google Scholar
• Lingani C, Bergeron-Caron C, Stuart JM, Fernandez K, Djingarey MH, Ronveaux O, Schnitzler JC, Perea WA. Meningococcal meningitis surveillance in the African meningitis belt, 2004–2013. Clin Infect Dis. 2015;61(Suppl 5):S410–415. doi:10.1093/cid/civ597. PMID:26553668.
   PubMed Web of Science ®Google Scholar
• Noah N, Henderson B. Surveillance of bacterial meningitis in europe 1999/2000. 2002. [accessed 2018 March 20] http://ecdc.europa.eu/en/publications/Publications/0202_SUR_Surveillance_of_Bacterial_Meningitis.pdf
   Google Scholar
• Larrauri A, Cano R, Garcia M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23(32):4097–100. doi:10.1016/j.vaccine.2005.03.045. PMID:15908059.
   PubMed Web of Science ®Google Scholar
• Menitorix (Meningococcal polysaccharide conjugate vaccine (Hib-MenC)). Full Prescribing Information, GlaxoSmithKline, Victoria, Australia, 2016.
   Google Scholar
• MENHIBRIX (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine ). Full Prescribing Information, GlaxoSmithKline, Rixensart, Belgium, 2013.
   Google Scholar
• Menactra® (MCV4). Full Prescribing Information. Sanofi Pasteur, 2011.
   Google Scholar
• Nimenrix®, Product Monograph. (Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine). Full Prescribing Information, Pfizer Canada Inc, Kirkland, QC, Canada, 2016.
   Google Scholar